DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20194104

Comparison of protective effects of carvedilol and α-tocopherol on doxorubicin-induced cardiotoxocity

Khalida Ajmal, Mohammad Ajmal, Ayesha Afzal, Saima ., Uzma Naeem, Abeera Sikandar

Abstract


Background: Doxorubicin, an effective anticancer drug used to treat multiple solid tumours and childhood malignancies since many decades but its cardiac adverse effects limits its use in full therapeutic dose. The mechanism involved in cardiotoxicity is apoptosis of cardiomyocytes due to reactive oxidative stress. The study was conducted to compare the cardioprotective effects of carvedilol and α-Tocopherol and to detect myocardial injury at early stage.

Methods: Cardiotoxicity was produced in a group of rabbits by single intravenous injection of doxorubicin; control group was treated with normal saline only. Third and fourth groups were pretreated with carvedilol 30 mg/kg bodyweight and α-Tocopherol 200 mg/kg bodyweight respectively for ten days before injection of doxorubicin.

Results: Doxorubicin produced marked cardiotoxicity represented by raised levels of serum biomarkers (cTnI, LDH and CK-MB) and severe necrosis of cardiomyocytes on microscopic examination. Carvedilol and α-tocopherol pretreatment resulted in decreased serum levels of biomarkers and improved the histological picture of heart tissue.

Conclusions: The outcome of doxorubicin chemotherapy can be made successful with the concurrent use of carvedilol or α-tocopherol. Although carvedilol has more pronounced cardioprotective effects perhaps due to its antioxidant activity in addition to antiapoptotic, antiproliferative and anti-inflammatory effects. Furthermore the quantitative cTnI estimation for detection of cardiotoxicity at early stage can lead to significant economic impact in management of cancer.


Keywords


Doxorubicin, Carvedilol, α-tocopherol, Cardiac troponin I, LDH, CK-MB

Full Text:

PDF

References


Schulz D, Nachtigall J, Geisen U, Kalthoff H, Imhoff JF, Fiedler HP, Süssmuth RD. Aranciamycin anhydride, a new anthracycline-type antibiotic isolated from Streptomyces. J Antibiot. 2010;63(7):397-9.

Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways:pharmacodynamics and adverse effects. Pharmacogenetics Genomics. 2010;21(7):440-6.

Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer:retrospective analysis of the Childhood Cancer Survivor Study cohort. Br Med J. 2009;339:b4606.

Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and Cardiotoxicity. Pharmacol Rev. 2004;56:185-229.

Matt S, Hofmann TG. The DNA damage-induced cell death response:a roadmap to kill cancer cells. Cellular Molecular Life Sci. 2016;73(15):2829–50.

L'Ecuyer T, Sanjeev S, Thomas R, Novak R, Das L, Campbell W, et al. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol. 2006;291(3):1273-80.

McGowan JV, Chung R, Maulik A, Piotrowska I., Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Thera. 2017;31(1):63–75.

Kankeu C, Clarke K, Passante E, Huber HJ. Doxorubicin-induced chronic dilated cardiomyopathy the apoptosis hypothesis revisited. J Mol Med. 2016;95(3):239–48.

Olson RD, Gambliel HA, Shadle SE, Cusack BJ. Doxorubicin cardiac dysfunction. Cardiovasc Toxicol. 2005;5(3):269-83.

Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639–42.

Cappetta D, Angelis AD, Sapio L, Prezioso L, Illiano M, Quaini F, et al. Oxidative Stress and Cellular Response to Doxorubicin:A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity Oxid Med Cell Longev. 2017;2017:1521020.

Ghigo A, Li M, Hirsch E. New signal transduction paradigms in anthracycline-induced cardiotoxicity. Biochim Biophys Acta. 2016;1863(7):1916-25.

Henriksen PA. Anthracycline cardiotoxicity: An update on mechanisms, monitoring and prevention. Heart. 2018;104:971–7.

Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1β and anti-erbB2:potential mechanism for trastuzumab-induced cardiotoxicity. Circulation. 2010;105:1551-4.

Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis. 2010;53(2):121-9.

Sawaya H, Sebag IA, Plana JC. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107:1375–80.

Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity:from bench to bedside. J Clin Oncol. 2008;26(22):3777–84.

Kalam K, Marwick HT. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. Euro J Cancer. 2013;49(13):2900-9.

Farías JG, Molina VM, Carrasco RA, Zepeda AB, Figueroa E, Letelier P, et al. Antioxidant therapeutic strategies for cardiovascular conditions associated with oxidative stress. Nutrients. 2017;1(9):966.

Jhorawat R, Kumari S, Varma SC, Rohit MK, Narula N, Suri V, et al. Preventive role of carvedilol in adriamycin-induced cardiomyopathy. Indian J Med Res. 2016;144(5):725–9.

Zhou Q, Xiao J, Jiang D, Wang R, Vembaiyan K, Wang A, et al. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med. 2011;17(8):1003-9.

Watanabe K, Arozal W, Sari FR, Arumugam S, Thandavarayan AR, Suzuki K, et al. The Role of Carvedilol in the Treatment of Dilated and Anthracyclines-Induced Cardiomyopathy. Kufa Med J. 2011;15(1):314.

Rehsia NS, Dhalla NS. Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. Exp Clin Cardiol. 2010;15(4):86-95.

Sari FR, Arozal W, Watanabe K, Harima M, Veeravedu PT, et al. Carvedilol Attenuates Inflammatory-Mediated Cardiotoxicity in Daunorubicin-Induced Rats. Pharmaceut 2011;4(3):551-66.

Sharma A, Herzo C. Beneficial effects of Carvedilol in dilated cardiomyopathy in dialysis patients. J Am Coll Cardiol. 2012;59(13):887.

Oliveira PJ, Bjork JA, Santos MS. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol. 2004;200:159-68.

Brigelius-Flohé R, Galli F. Vitamin E:A vitamin still awaiting the detection of its biological function. Mol. Nutr. Food Res. 2010;54:583–8.

Ajmal K, Khan BT, Hashim R, Bakhtiar B. Doxorubicin-Induced Cardiotoxocity Detection. Pak Armed Forces Med J. 2014;64(3):384-90.

Atkinson J, Harroun T, Wassall SR, Stillwell W, Katsaras J. The location and behaviour of -tocopherol in membranes. Mol Nutr Food Res. 2010;54(5):641-51.

Zinng JM. Molecular and cellular activities of vitamin E analogues. Mini Rev Med Chem. 2014;7(5):543-58.

Jiang Q. Natural Forms of Vitamin E as Effective Agents for Cancer Prevention and Therapy. Advac in Nutri. 2017;8(6):850–67.

Simunek T, Sterba M, Popelova O, Adamcova M, Hrdina R, Gesi V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacolo Repo. 2009;61(1):154–71.

Che FF, Liu Y, Xu CG. Schisandrin B prevents doxorubicin-induced cardiotoxicity in rabbits. Sichuan Da Xue Xue Bao Yi Xue Ban. 2010;41(1):24-8.

Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2016. National Cancer Institute, Bethesda, MD. 2017.

Hadi N, Yousif GN, Al-amran GF, Huntei NK, Mohammad BI, Ali SJ. Vitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response. BMC Cardiovasc Disorders. 2012;12:63.

Arozal W, Sari RF, Watanabe K, Arumugam S, Thandavarayan AR, Suzuki K. Carvedilol Attenuates Inflammatory-Mediated Cardiotoxicity in Daunorubicin Induced Rats. Pharmaceuticals. 2011;4(3):551-66.

Cochera F, Dinca D, Bordejevic DA, Citu IM, Mavrea AM, Andor M, et al. Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer. Cancer Management Res. 2018;10:2071-81.

Abbas A, Hadi A, Saeed CA, Ali C, Reza T, Sadaf D, Soheila R. Protective effects of omega-3, atorvastatin, vitamin E and vitamin C against doxorubicin-induced cardiotoxicity in rats: a comparison study. Physiol Pharmacol. 2018;22:63-72.